How is European Immuno-Oncology fighting Blood Cancer?

06/12/2016 - 4 minutes

From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field.

The 58th ASH annual meeting is wrapping up today, after the best companies and research institutions showed off their latest achievements towards a cure for blood diseases. Among its top-level participants, eight European biotechs have announced data on immuno-oncology therapies.

These approaches represent a huge leap towards developing a cure for cancer by using the patient’s own immune system to fight against tumors. In particular, liquid tumors are the easiest target, making blood cancer one of the most important fields for biotech companies to prove their concepts.

Novartis CAR-T

With Juno Therapeutics out of the race after multiple deaths in the clinic, Novartis has taken the lead in chimeric antigen receptor T-cell (CAR-T) therapy with positive results for CTL019 in Phase II trials to treat B-cell acute lymphoblastic leukemia (ALL),

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member